Cidofovir

Drug Profile

Cidofovir

Alternative Names: Forvade®; GS 504; HPMPC; Vistide

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer Gilead Sciences; Institute of Organic Chemistry and Biochemistry (Prague); Pfizer; Rega Institute for Medical Research; University of Texas M. D. Anderson Cancer Center
  • Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cytomegalovirus retinitis
  • No development reported Cystitis
  • Discontinued Cancer; Herpes simplex virus infections; Human papillomavirus infections; Kaposi's sarcoma; Molluscum contagiosum; Polyomavirus infections; Rheumatic disorders; Viral infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cystitis in USA (Intravesicular, Liquid)
  • 01 Dec 2016 Gilead Sciences completes a phase I trial in Cystitis (in patients who have undergone haematopoietic stem cell transplant) in USA (Intravesicular) (NCT01816646)
  • 06 Sep 2013 Phase-I clinical trials in Cystitis (in patients who have undergone haematopoietic stem cell transplant) in USA (Intravesicular) (NCT01816646)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top